Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Domino's Pizza, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Domino's Pizza, Inc. trades at $304.36 (market cap $10.42B). The key difference: Domino's Pizza, Inc. is far larger — about 2.3× ACADIA Pharmaceuticals Inc.'s market cap, and Domino's Pizza, Inc. pays a 2.54% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DPZ | |
|---|---|---|
Market Cap | $4.49B | $10.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $485.53 |
52-Week Low | $20.06 | $282.89 |
Enterprise Value | $3.69B | $15.32B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Domino's Pizza (DPZ) trades at $313.14, up 0.47% on the day, but remains near its 52-week low amid a bearish technical trend. The company reported mixed Q1 2026 earnings with an EPS miss of $4.13 vs. $4.27 expected, though revenue growth has been steady, reaching $4.94B in 2025. Analyst consensus is bullish with a $386.07 price target, but recent CEO transition and slowing same-store sales present near-term headwinds. Cash flow from operations remains strong at $792M in 2025, supporting dividends and buybacks.
DPZ offers value with a P/E of 17.6x and solid profitability (net margin 11.9%), but high debt levels and competitive pressures pose risks. The stock's 25% YTD decline creates a potential entry point for long-term investors, though execution under new leadership and consumer spending trends will be critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
